吉非替尼-一个潜在的治疗肺癌的新选择

Future Prescriber Pub Date : 2009-04-28 DOI:10.1002/fps.47

Dr Fiona Blackhall, Steve Chaplin

{"title":"吉非替尼-一个潜在的治疗肺癌的新选择","authors":"Dr Fiona Blackhall, Steve Chaplin","doi":"10.1002/fps.47","DOIUrl":null,"url":null,"abstract":"Lung cancer is the second most common cancer in the UK, accounting for one in seven new cases, 24% of cancer deaths among men and 20% among women.1 In this article, Dr Fiona Blackhall and Steve Chaplin consider the use of gefitinib for lung cancer its mechanism of action, efficacy and adverse effects are described, followed by its effect on quality of life and its potential place in disease management. Pharmacist Geoff Saunders provides a commentary on the article and remarks on the selective use of gefitinib in lung cancer therapy. Copyright © 2009 John Wiley & Sons, Ltd.","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 2","pages":"7-13"},"PeriodicalIF":0.0000,"publicationDate":"2009-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.47","citationCount":"2","resultStr":"{\"title\":\"Gefitinib - a potential new treatment option in lung cancer\",\"authors\":\"Dr Fiona Blackhall, Steve Chaplin\",\"doi\":\"10.1002/fps.47\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lung cancer is the second most common cancer in the UK, accounting for one in seven new cases, 24% of cancer deaths among men and 20% among women.1 In this article, Dr Fiona Blackhall and Steve Chaplin consider the use of gefitinib for lung cancer its mechanism of action, efficacy and adverse effects are described, followed by its effect on quality of life and its potential place in disease management. Pharmacist Geoff Saunders provides a commentary on the article and remarks on the selective use of gefitinib in lung cancer therapy. Copyright © 2009 John Wiley & Sons, Ltd.\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"10 2\",\"pages\":\"7-13\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.47\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.47\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

肺癌是英国第二大常见癌症，占新病例的七分之一，占男性癌症死亡人数的24%，占女性癌症死亡人数的20%在这篇文章中，Fiona Blackhall博士和Steve Chaplin博士考虑使用吉非替尼治疗肺癌，描述了它的作用机制、疗效和不良反应，其次是它对生活质量的影响及其在疾病管理中的潜在地位。药剂师Geoff Saunders对这篇文章进行了评论，并评论了吉非替尼在肺癌治疗中的选择性使用。版权所有©2009 John Wiley &儿子,有限公司

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Gefitinib - a potential new treatment option in lung cancer

Lung cancer is the second most common cancer in the UK, accounting for one in seven new cases, 24% of cancer deaths among men and 20% among women.¹ In this article, Dr Fiona Blackhall and Steve Chaplin consider the use of gefitinib for lung cancer its mechanism of action, efficacy and adverse effects are described, followed by its effect on quality of life and its potential place in disease management. Pharmacist Geoff Saunders provides a commentary on the article and remarks on the selective use of gefitinib in lung cancer therapy. Copyright © 2009 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量